Iovance, A Top 1% Biotech Stock, Crashes In A Surprise Lung Cancer Twist

Iovance stock crashed Thursday, undercutting its 50-day line, on new durability questions for its experimental lung cancer treatment.

Investors Business Daily • 6 hours ago

Iovance's Lifileucel Shows 25% Lung Cancer Response Rate, Targets 2027 FDA Filing

Iovance Biotherapeutics NASDAQ: IOVA reported updated data from its registrational IOV-LUN-202 trial of lifileucel in previously treated, non-squamous metastatic non-small cell lung cancer, outlining plans for a supplemental Biologics License Application submission in 2027 and a new biomarker-enriched study.

MarketBeat • 4 hours ago

Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC)

24.6% Objective Response Rate (ORR) in 69 Patients with Non-Squamous mNSCLC, Consistent with Previously Reported Results IOV-LUN-202 Cohorts 1 and 2 Are Completing Enrollment and Support a Planned Supplemental Biologics License Application (sBLA) for Lifileucel in Non-Squamous mNSCLC in 2027 KRAS Wild-Type Subgroup Achieved 43.3% ORR Versus 11.4% in KRAS-Mutant Disease and Novel Biomarker-Enriched Subgroup Achieved 59.1% ORR POSITILITY, a First-In-Class Biomarker-Enriched Study with Registrational Intent, to Begin Enrollment in November 2026 PHILADELPHIA, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company developing and delivering tumor infiltrating lymphocyte (TIL) therapies for cancer, today announced updated results from Cohorts 1 and 2 of its Phase 2 IOV-LUN-202 trial and a first-in-class biomarker-enriched precision TIL strategy for lifileucel in previously treated non-squamous mNSCLC. IOV-LUN-202 Cohorts 1 and 2 are completing enrollment and support the planned sBLA for lifileucel in non-squamous mNSCLC in 2027.

GlobeNewsWire • 10 hours ago

Iovance Biotherapeutics (IOVA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Iovance Biotherapeutics (IOVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • 6 hours ago

Iovance Biotherapeutics, Inc. (IOVA) Discusses Positive Lifileucel Data and Precision TIL Strategy in Non-small Cell Lung Cancer Transcript

Iovance Biotherapeutics, Inc. (IOVA) Discusses Positive Lifileucel Data and Precision TIL Strategy in Non-small Cell Lung Cancer Transcript

Seeking Alpha • 3 hours ago

Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy

Live Webcast at 8:30 a.m. ET on Thursday, October 29, 2026 PHILADELPHIA, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast on Thursday, October 29, 2026 at 8:30 a.m.

GlobeNewsWire • a day ago

Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026

PHILADELPHIA, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast on Thursday, November 5, 2026 at 8:30 a.m. ET to report its third quarter 2026 financial results and corporate updates.

GlobeNewsWire • Oct 27, 2026

New Strong Buy Stocks for October 27th

NTSK, PRMRF, IOVA, CAPL and MEI have been added to the Zacks Rank #1 (Strong Buy) List on October 27th, 2026.

Zacks Investment Research • Oct 27, 2026

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Zacks Investment Research • Oct 27, 2026

Best Momentum Stocks to Buy for October 27th

IOVA, MEI and PRMRF made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 27th, 2026.

Zacks Investment Research • Oct 27, 2026